source
- Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns lingerHelus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…
- CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trialCG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…